Health Claims

In a group of 32 people with type 2 diabetes, taking oral semaglutide for 6 months led to a noticeable drop in body fat, with an average loss of about 17.6% of their initial fat mass.

Among HIV patients with high liver enzymes, 35% of those who lost at least 8% visceral fat from the drug had their ALT levels return to normal after six months, compared to 18% of those who didn't lose much fat.

HIV patients with belly fat and high liver enzymes who lost at least 8% of their visceral fat from the drug saw their ALT drop by about 9 points (18%) and AST by 4 points (10%) after six months of treatment.

HIV patients with high liver enzymes who lost visceral fat from the drug kept their liver enzyme levels improved for a full year even after stopping the drug and some fat coming back.

Whether HIV patients had hepatitis or not didn't change the link between losing visceral fat and improving liver enzyme levels.

For HIV patients with belly fat and high liver enzymes, taking a placebo even if they lost visceral fat didn't help lower their liver enzyme levels, unlike those taking the actual drug.

HIV patients with high liver enzymes who lost at least 8% of their visceral fat from the drug were 2.5 times more likely to have their ALT levels return to normal compared to those who didn't lose much fat.

In people with HIV and belly fat, having more visceral fat was linked to higher levels of a liver enzyme called ALT, which suggests a connection between belly fat and liver health.

For people with HIV and belly fat who have high liver enzyme levels, those who lost at least 8% of their visceral fat from the drug had much bigger drops in their liver enzyme numbers compared to those who didn't lose much fat, and this difference was statistically significant.

For people with HIV and fatty liver on INSTI drugs, taking tesamorelin for a year likely reduces liver fat by 4.9% compared to a tiny 0.1% reduction in those on a placebo.

For people with HIV and fatty liver on INSTI drugs, taking a placebo for a year leads to a 10.8% increase in belly fat.

Out of 61 people with HIV and fatty liver in the study, 39 were on INSTI drugs, and most of those (41%) were taking dolutegravir.

For people with HIV and fatty liver on INSTI drugs, taking tesamorelin for a year likely reduces liver fat by 31% compared to their starting point, which is much better than the tiny change seen in those on a placebo.

For people with HIV and fatty liver who are on INSTI drugs, taking tesamorelin for a year likely reduces belly fat by 8.3%, while those on a placebo see a 10.8% increase in belly fat.

Strength training alone helps middle-aged men build muscle and lose fat, but adding this collagen supplement makes those improvements even better.

Middle-aged men doing strength training don't change their protein intake whether they take collagen, whey, or a placebo.

Adding this collagen supplement to strength training doesn't help middle-aged men reduce waist size more than a placebo or whey protein.

Doing strength training alone helps middle-aged men build stronger bones, but adding this collagen supplement doesn't make a bigger difference than a placebo or whey protein.

Strength training with this collagen supplement doesn't make middle-aged men significantly stronger in leg presses than taking a placebo.

For middle-aged men doing strength training, whey protein and this collagen supplement have similar effects on muscle gain and fat loss.

Middle-aged men doing strength training and taking this collagen supplement lose 1.9 kg more body fat than those taking a placebo.

Middle-aged men doing strength training and taking this collagen supplement build 1.6 kg more muscle than those taking a placebo.

For people with HIV and fatty liver on INSTI drugs, tesamorelin reduced liver fat by 31% compared to their starting point, which was a significant improvement. This finding is from the abstract summary - full study details were not available

For people with HIV and fatty liver on INSTI drugs, tesamorelin lowered liver fat by 4.9% compared to almost no change (0.1%) in the placebo group, which was a significant difference. This finding is from the abstract summary - full study details were not available